Header Logo

Connection

Sunita Nathan to Aged

This is a "connection" page, showing publications Sunita Nathan has written about Aged.
Connection Strength

0.339
  1. Acute splenic sequestration crisis in adults with hemoglobin S-C disease: a report of nine cases. Ann Hematol. 2006 Apr; 85(4):239-43.
    View in: PubMed
    Score: 0.025
  2. Scedosporium infection disseminated "from toe to head" in allogeneic stem cell transplant recipient: a case report. BMC Infect Dis. 2023 May 25; 23(1):353.
    View in: PubMed
    Score: 0.020
  3. The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. Haematologica. 2023 01 01; 108(1):150-160.
    View in: PubMed
    Score: 0.020
  4. Transplantation provides superior survival high risk myeloid malignancies in older patients. Leuk Lymphoma. 2022 10; 63(10):2494-2498.
    View in: PubMed
    Score: 0.019
  5. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. JAMA Oncol. 2022 Mar 01; 8(3):404-411.
    View in: PubMed
    Score: 0.019
  6. Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. Transplant Cell Ther. 2021 11; 27(11):921.e1-921.e10.
    View in: PubMed
    Score: 0.018
  7. Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood. 2021 06 10; 137(23):3291-3305.
    View in: PubMed
    Score: 0.018
  8. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia. 2021 09; 35(9):2672-2683.
    View in: PubMed
    Score: 0.018
  9. Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. Transplant Cell Ther. 2021 01; 27(1):68.e1-68.e9.
    View in: PubMed
    Score: 0.017
  10. Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. Int J Lab Hematol. 2021 02; 43(1):e19-e25.
    View in: PubMed
    Score: 0.017
  11. Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy. Br J Haematol. 2020 10; 191(1):44-51.
    View in: PubMed
    Score: 0.017
  12. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. Br J Haematol. 2020 08; 190(4):573-582.
    View in: PubMed
    Score: 0.017
  13. Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation. Cancer. 2020 05 15; 126(10):2279-2287.
    View in: PubMed
    Score: 0.016
  14. Allogeneic transplantation in elderly patients =65 years with non-Hodgkin lymphoma: a time-trend analysis. Blood Cancer J. 2019 12 03; 9(12):97.
    View in: PubMed
    Score: 0.016
  15. Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. Clin Cancer Res. 2019 08 15; 25(16):5143-5155.
    View in: PubMed
    Score: 0.016
  16. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Adv. 2019 06 25; 3(12):1826-1836.
    View in: PubMed
    Score: 0.016
  17. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. 2019 01 10; 12(1):6.
    View in: PubMed
    Score: 0.015
  18. Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. Biol Blood Marrow Transplant. 2018 03; 24(3):486-493.
    View in: PubMed
    Score: 0.014
  19. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. Br J Haematol. 2016 07; 174(2):235-48.
    View in: PubMed
    Score: 0.012
  20. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma. Oncology. 2013; 84(2):123-6.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.